Esther Méndez Arias: Why a Lower First Dose of 4F-PCC Works Better After Cardiac Surgery
Esther Méndez Arias, President of the Transfusion Committe at Bellvitge University Hospital, Coordinator of the Working Group on Digital Transformation and Innovation, Spanish Society of Anaesthesiology at SEDAR, shared Journal Cardiothoracic Vascular Anesthesia‘s post on LinkedIn:
“At our centre, we usually administer 10–15 IU/kg of four-factor prothrombin complex concentrate for bleeding after cardiac surgery, once residual heparin, hypofibrinogenaemia and platelet abnormalities have been corrected.
We then reassess both bleeding and ROTEM findings, and administer a second dose only if microvascular bleeding and coagulopathy consistent with coagulation factor deficiency persist.
For this reason, the median dose of 3,000 IU —approximately 36 IU/kg— used in the retrospective study by Vander Zwaag et al. seems excessive to us as an initial strategy.
We favour a stepwise approach: a low initial dose, early reassessment and redosing only when necessary, without attempting to normalise an isolated EXTEM-CT value.
This is in line with the European consensus by Erdoes et al., developed within the EACTA, which suggests considering an initial dose of 12.5 IU/kg in patients at high thromboembolic risk, such as those undergoing cardiac surgery.”
Journal Cardiothoracic Vascular Anesthesia shared a post on LinkedIn about recent article by Daniel Bolliger et al, published in JCVA, adding:
“How To Dose Prothrombin Complex Concentrates in Bleeding Patients After Cardiac Surgery
How should we dose prothrombin complex concentrate in bleeding cardiac surgery patients?
This editorial argues that ROTEM clotting time poorly reflects thrombin generation, cautioning against high doses and purely viscoelastic-guided dosing.”
Title: How To Dose Prothrombin Complex Concentrates in Bleeding Patients After Cardiac Surgery
Authors: Daniel Bollige, Eckhard Mauermann, Kenichi A. Tanaka

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 12, 2026, 16:35Mohamed Hesham Gamal: Intravenous Thrombolysis Shows Strong Safety Profile in Stroke Mimics
-
Nov 12, 2026, 14:35Mokhtar Tazik: Connecting Clinical Demand with Plasma Collection and Fractionation Capacity
-
Nov 12, 2026, 14:25Kim Phelan: Celebrating Dr. Marilyn Manco-Johnson as a Recipient of the 2026 Eternal Spirit Award
-
Nov 12, 2026, 14:20Shailesh Kucha: Ensuring Transfusion Safety Through Biochemical Assessment of Stored Red Cells
-
Nov 12, 2026, 14:20Akshat Jain: Wonderful Time Presenting at the ATHN 2026
-
Nov 12, 2026, 14:08Elisa Gabinaud: The Evolving Science of Megakaryocyte Development
-
Nov 12, 2026, 13:57Seyed Mohammad Sadegh Pezeshki: When Microcytosis Reveals a Complex Hemoglobinopathy
-
Nov 12, 2026, 13:45Danny Hsu: THANZ Highlights Antiphospholipid Syndrome in Upcoming Educational Webinar
-
Nov 12, 2026, 13:04Wuhan Thrombosis Congress 2026 – Bringing Global Experts Together – ISTH